Peptide News Digest

#Cell-Immunotherapy

2 stories

Clinical Trials · View digest

BriaCell Bria-IMT ASCO 2026 Biomarker Detail: 65% of Heavily Pretreated Breast Cancer Patients Showed CAML Stability/Drop Correlating With Better Progression-Free Survival

BriaCell's ASCO 2026 poster presentations added a biomarker finding beyond the headline 16.6-month median overall survival for Bria-IMT. In an ongoing analysis of heavily pretreated metastatic breast cancer patients, 65% showed stability or a drop in Cancer-Associated Macrophage-Like cells (CAMLs) — circulating cells in the blood that reflect tumor activity — and that change significantly correlated with better progression-free survival. The CAML biomarker offers a potential early blood-based readout of Bria-IMT response, which matters for an immunotherapy where conventional imaging can lag the immune response. BriaCell's six ASCO 2026 data items (three posters, three publication-only abstracts) cover the pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor plus further Phase 2 analyses. Bria-IMT is a whole-cell allogeneic peptide-and-cell immunotherapy in heavily pretreated metastatic breast cancer that has failed ADC, checkpoint, and CDK4/6 inhibitor therapy. The biomarker work supports patient selection and response monitoring as the program advances toward accelerated-approval discussions.

Clinical Trials · View digest

BriaCell ASCO 2026 Final Phase 2 Bria-IMT Survival Data (May 21): Cell-Immunotherapy + Checkpoint Inhibitor in Heavily Pretreated Metastatic Breast Cancer

BriaCell released final randomized Phase 2 Bria-IMT survival and quality-of-life data at ASCO 2026 alongside biomarker analyses from the ongoing Phase 3 study. Bria-IMT — a whole-cell allogeneic peptide-and-cell immunotherapy combined with checkpoint inhibitor — has been studied in heavily pretreated metastatic breast cancer patients who have failed antibody-drug conjugate, checkpoint, and CDK4/6 inhibitor therapy. The Phase 2 data set covers 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The Phase 3 program added Penn Medicine's Abramson Cancer Center as a site on May 13, joining Smilow Cancer Hospital at Yale New Haven and the Los Angeles Cancer Network. The six-abstract BriaCell package at ASCO 2026 — three poster presentations and three publication-only abstracts — establishes the company as the largest peptide-immunotherapy presence at this year's meeting.